Evaluation Of Solid Lipid Nanoparticles Research Articles

Design Optimization and Evaluation of Solid Lipid Nanoparticles of Azelnidipine for the treatment of Hypertension.

Solid lipid nanoparticles (SLN) are the most promising lipid-based drug delivery utilized for enhancing the solubility, bioavailability, and therapeutic efficacy of poorly water-soluble molecules. Azelnidipine (AZN) is a calcium channel blocker widely recommended for the treatment of high blood pressure but its activity is restricted due to high lipophilicity and poor solubility in the GIT. The current research focused on the development of the SLN of AZN and thereby improving the absorption, bioavailability, and therapeutic efficacy in hypertension which is a leading cause of death worldwide. Recent patents on SLN was available as U.S. Patent,10,973,798B2, U.S. Patent 10,251,960B2, U.S. Patent 2021/0069121A1, U.S. Patent 2022/0151945A1. SLN was developed by hot melt emulsification and ultrasonication method using glyceryl monostearate (GMS) as solid lipid and Poloxamer 188 as a surfactant for the stabilization of colloidal dispersion. Box-Behnken model was utilized which predicted 13 batches in which concentration of GMS (X1), Poloxamer 188 (X2) and sonication time (X3) were considered as independent parameters. The particle size (Y1) and entrapment efficiency (Y2) were dependable parameters and optimized batch F2 showed a particle size of 166.4 nm, polydispersity index of 0.40 and zeta potential of -13.7 mV. The entrapment efficiency was observed at 86.21 %. FTIR spectra confirm the identity and compatibility with the formulation components. The differential scanning calorimetry (DSC) confirmed the absence of melting point and interpreted that AZN was entirely incorporated in the lipid matrix and transformed from crystalline to amorphous form. The ANOVA for the particle size (p-value: 0.0203), % EE (p-value: 0.0271) was found significant. The in-vitro drug release showed a sustained release pattern for about 12 h. The AZN-loaded SLN was lyophilized and intended for oral delivery. AZN-loaded SLN was developed by the hot melt emulsification method which accelerated the solubility and bioavailability and released in a sustained manner for treating hypertension.

Formulation and evaluation of solid lipid nanoparticles of naringin to enhance its bioavailability

The objective of the present work was to formulate solid lipid nanoparticles loaded with naringin for improving the bioavailability of naringin. The SLNs loaded with naringin were prepared by using different ratio of palmitic and stearic acid as the lipids and Tween 80 as the surfactant. The method nanoprecipitation was used for preparation of the SLNs. The surfactant (Tween 80) helps in steric stabilization of the SLNs. The size range of SLNs obtained on sonicating for 7 was found to be 429 ± 76 nm when stearic acid was used and 365 ± 28 nm when palmitic acid was used for the preparation of SLNs. The zeta potential of all the SLNs ranged from -16 to -27 mV suggesting a stable formulation. The percentage of drug incorporated during nanoparticle preparation was determined by centrifuging the drug loaded nanoparticles at 15,000 rpm for 15 min and separating the supernatant. The highest encapsulation of naringin (71.7 ± 8.6 %) was obtained when the concentration of palmitic acid was 0.14 mmol. The in vitro release of naringin from the SLNs was measured by dialysis method using simulated gastric fluid as the dissolution medium. In vitro release kinetics studies for naringin loaded SLNs exhibited a sustained release pattern. Sustained release was observed over a period of 3 days. The stability of NSLN-7 was studied by storing at 4 ± 1 °C for 30 days. The particle size remained stable at the end of the study with drug entrapment of 71.5 %. This suggests that the SLNs prepared are stable on storage.

WITHDRAWN: Development, Optimization and Evaluation of Solid Lipid Nanoparticles of Celecoxib.

The article has been withdrawn at the request of the authors of the journal Pharmaceutical Nanotechnology. Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused. The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/pages/editorial-policies-main Bentham Science Disclaimer: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.

Formulation and evaluation of solid lipid nanoparticles loaded with papaya seed chloroform extract for long-term antifertility effects on the male rat, Bandicota bengalensis

The study is the first to formulate and investigate potential of papaya seed chloroform extract based solid lipid nanoparticles (PSCEN) as antifertility agents on male Bandicota bengalensis. The prepared nanoparticles were spherical of size 300–600 nm. The release kinetics showed a controlled release of the drug with major release over 48 h. To assess the antifertility effects of PSCEN, adult male rats were fed a diet containing two different concentrations of PSCEN (5% and 10%) for 15 days under bi-choice conditions. The mean total active ingredient ingestion of the rats in the two treated groups ranged from 2.13–3.31 and 3.92–5.87 g/100g body weight, respectively. No adverse effects of treatment on body weight were observed. Also, no mortality of rats was observed. The treatment had a significant effect on the weight of the testis and the epididymis, but not on the other organs. Sperm motility (%), sperm viability (%), sperm count (millions/ml), sperm mitochondrial activity (%), sperm nuclear chromatin de-condensation (%) and sperm hypo-osmotic swelling (%) were significantly decreased, and sperm abnormality (%) significantly increased compared to the vehicle control group. The reproductive success rates of male rats treated with 5% and 10% PSCEN and mated with untreated female rats were 20.00–66.67% and 16.67%, respectively, while in untreated female rats mated with male rats of vehicle control group, reproductive success rate was 33.33 to 80%. The study found a maximal antifertility effect of the 10% PSCEN containing bait, which was irreversible up to 105 days after stopping treatment, suggesting long-term efficacy.

Development and Evaluation of Solid Lipid Nanoparticles for the Clearance of Aβ in Alzheimer’s Disease

Aggregation of Amyloid-β (Aβ) leads to the formation and deposition of neurofibrillary tangles and plaques which is the main pathological hallmark of Alzheimer's disease (AD). The bioavailability of the drugs and their capability to cross the BBB plays a crucial role in the therapeutics of AD. The present study evaluates the Memantine Hydrochloride (MeHCl) and Tramiprosate (TMPS) loaded solid lipid nanoparticles (SLNs) for the clearance of Aβ on SHSY5Y cells in rat hippocampus. Molecular docking and in vitro Aβ fibrillation were used to ensure the binding of drugs to Aβ. The in vitro cell viability study showed that the M + T SLNs showed enhanced neuroprotection against SHSY5Y cells than the pure drugs (M + T PD) in presence of Aβ (80.35µM ± 0.455 µM) at a 3:1 molar ratio. The Box-Behnken Design (BBD) was employed to optimize the SLNs and the optimized M + T SLNs were further characterized by %drug entrapment efficiency (99.24 ± 3.24 of MeHCl and 89.99 ± 0.95 of TMPS), particle size (159.9 ± 0.569 nm), PDI (0.149 ± 0.08), Zeta potential (-6.4 ± 0.948 mV), Transmission Electron Microscopy (TEM), Atomic Force Microscopy (AFM) and in vitro drug release. The TEM & AFM analysis showed irregularly spherical morphology. In vitro release of SLNs was noted up to 48 h; whereas the pure drugs released completely within 3 hrs. M + T SLNs revealed an improved pharmacokinetic profile and a 4-fold increase in drug concentration in the brain when compared to the pure drug. Behavioral tests showed enhanced spatial memory and histological studies confirmed reduced Aβ plaques in rat hippocampus. Furthermore, the levels of Aβ decreased in AlCl3-induced AD. Thus, all these noted results established that the M + T SLNs provide enhanced neuroprotective effects when compared to pure and individual drugs and can be a promising therapeutic strategy for the management of AD.

Design and Evaluation of Solid Lipid Nanoparticles Loaded Topical Gels: Repurpose of Fluoxetine in Diabetic Wound Healing.

The current study aimed to prepare a topical gel containing solid lipid nanoparticles (SLNs) encapsulating fluoxetine for diabetic wound healing effects. Fluoxetine (FX) was loaded into SLNs by employing an emulsion solvent evaporation technique using stearic acid as a lipid, and soya lecithin as a surfactant. SLNs were then evaluated for particle size, polydispersity index (PDI), zeta potential (ZP), percent entrapment efficiency (%EE), percent drug loading (%DL), and in vitro drug release. The optimized SLN (FS3) composed of FX (100 mg), SA (150 mg), and SA (100 mg) displayed mean particle size (467.3 ± 2.2nm), PDI (0.435 ± 0.02), ZP (-32.2 ± 4.47mV), EE (95.8 ± 3.38%), and DL (16.4 ± 2.4%). FTIR and DSC studies denote drug-polymer compatibility and the amorphous nature of FX in the SLNs. The drug release at 24 h was found to be (98.89 ± 2.57%) which followed the fickian diffusion mechanism. SLN (FS3) was further loaded into carbopol gel and tested for pH, spreadability, and extrudability of pharmaceutical parameters. In-vitro release of FX from the SLN gel and plain gel was compared, diabetic wound healing gel (DWH) showed sustained drug delivery. An in vivo study was also performed for DWH gel in streptozotocin-induced diabetic rats. Histopathological examination exhibited DWH gel-treated wounds have increased hydroxyproline, cellular proliferation, a rise in the number of blood vessels, and the level of collagen synthesis. Thus, DWH gel-loaded SLN encapsulated with FX could be a potential carrier for the effective treatment and management of diabetic wounds.

Formulation and Evaluation of Solid Lipid Nanoparticles containing Kappaphycus alvarezii Extract in A Cosmetic Gel

Objectives: The objective of the research was to prepare and evaluate the cosmetic gel containing SLNs of Kappaphycus alvarezii chloroform extract to localize the extract topically to exert its antimicrobial properties. Methodology: The antimicrobial activity evaluation for the chloroform, methanol, and aqueous K. alvarezii extracts were carried out using disc-diffusion agar plate method. The extract with maximum antimicrobial action was selected for the preparation of SLNs. Pre-formulation studies using ATR-FTIR spectrophotometer was carried out to check the compatibility of the extract with excipients in the range of 400–4000 cm−1.The SLNs were prepared by the film hydration technique with ultrasonication. The dried SLNs were evaluated for its physical characteristics, zeta potential and for the duration taken to release the encapsulated extract for the antimicrobial action. Carbopol and HPMC were chosen as the gelling agent after compatibility studies with nanoparticle dispersions.The extract loaded SLNs based gel was analysed for its pH, visual appearance, and in-vitro drug release. Results: Chloroform extract of K. alvarezii (120μg) showed maximum antimicrobial activity with cloudy and blurry zone of inhibition. The zone of inhibition was smaller for SLNs when compared to the extract. This was due to the low diffusion of encapsulated drug through the outer lipid layer of SLNs. SLNs showed a zeta potential ranging between –11.0 to –37.4mV. The formulated gel containing solid lipid nanoparticles of chloroform extract of K. alvarezii had an average pH value of 5.37, which was suitable to be used on human skin. The maximum drug release was 60.28% for over a period of 25 hours. Conclusion: In this study algal extracts were successfully encapsulated within the SLNs and when applied topically the SLNs could reside on the surface of the skin for localized action as evident from the drug release study.The zeta potential obtained for the SLNs was approximately within the limit of –30mV that yields a formulation with fairly good physical stability.

A COMPARATIVE STUDY OF SOLUBILITY ENHANCEMENT OF BICALUTAMIDE BY SOLID LIPID NANOPARTICLES AND SOLID DISPERSION TECHNIQUE

A comparative evaluation of solid lipid nanoparticles and solid dispersion of bicalutamide using PVP K30 and stearic acid was performed. Bicalutamide solid dispersions (BL- SD) were prepared with conventional solvent evaporation method and bicalutamide solid lipid nanoparticles (BL-SLN) were prepared by precipitation method. The formulations were assessed on the standard evaluation parameters. The study demonstrated that BL-SLN was performed better as compared to (BL- SD).

Design and Evaluation of Solid Lipid Nanoparticles of an Antibiotic-mannitol as Cryoprotectant

Mannitol was used as a cryoprotactant to freeze-dry Doxycycline nanoparticles for colloidal drug administration in this work. in this research, the benefits include Medicines like vaccines and other injectables, which have a short shelf life and are commonly freeze-dried to increase their shelf life. A liquid may be treated more easily with aseptic handling because of this. The stability of a dry powder has been increased. In addition, water may be removed from the device without causing it to overheat. Reconstituted product dissolves quickly and readily. All of these concerns are avoided so that the product may be transported or stored at room temperature without suffering deterioration or degradation due to aggregation. Preparation of doxycycline SLNs included homogenization and sonication. Antimicrobial activity and in vitro anticancer activity are among the techniques employed in this investigation. Freeze drying was also a component of the process, as was particle size, drug loading, and drug release. The lipid solid’s particle size distribution At various magnifications of the investigation, nanoparticles are determined to be 3.66, 6.58, 9.96, 4.97, 17.36, and 25.48mm in diameter. A freeze-dryer was used to freeze-dry the particles at -20°C and 0.4 pressure. Mannitol at various concentrations (5, 10, and 15 percent) was utilised as a cryoprotectant. Drug loading was determined to be 78 percent, while drug release was found to be 98 percent after 24 hr. Maximum inhibition of cell growth (69.9422) was seen at an IC50 concentration of 100g/mL of leaf crude extract (48.69g/mL). Doxycycline SLNs might be inferred to be more stable, less aggregate, and have fewer adverse effects when freeze-dried.

Formulation and Evaluation of Solid Lipid Nanoparticles Loading Erythromycin Ethylsuccinate by Heating Emulsification and Homogenization Methods

The pandemic period has caused antibiotics highly recommended to cure infections. The use of macrolide antibiotics has greatly increased recently due to outbreaks of diseases that attack the human respiratory tract all of part of the world. One member of the macrolide group is erythromycin ethyl succinate which has low solubility in water. Therefore, this study aims to convert erythromycin ethyl succinate into lipid nanoparticles in an attempt to increase solubility. The method for the formation of nanoparticles is heating emulsification and homogenization. The results obtained in the form of formula 1 (F1) showed the percent encapsulation of 85.688±0.30641. The physical properties were that it has a size of 398.9±1.4 nm, a PDI of 0.3895±0.0015, and zeta potential of -17.45±0.15 mV respectively. The stability was determined by an accelerated test by the influence of extreme temperature and mechanics affecting the stability of the particles as an indication of decreasing the pH and particle precipitation. The solubility of erythromycin ethyl succinate in the form of lipid nanoparticles was increased in a comparison with the pure substance of erythromycin ethyl succinate.

Formulation and Development of Nanostructured Lipid Carriers for a Poorly Water-Soluble Drug: Furosemide

Aim: Formulation, development and evaluation of solid lipid nanoparticles. Background: It was found that furosemide (FU) was a very potent drug but it fails to produce bioavailability due to its BCS class IV, so drug- cyclodextrin (CD)- nanostructured lipid carriers (NLC) will be an alternative to improve solubility and permeability as a result of this overall bioavaibility will be improved. Objective: To improve the solubility of drug by using complexation of cyclodextrin. Coating with the lipids (NLC) will improve the permeability of the drug. Methods: To generate solid Furosemide–cyclodextrin complexes (FU–CD), two distinct CDs and three different techniques were used. The co-evaporation (COE) Furosemide-β-cyclodextrinloaded NLC (FU– β-CD-COE-loaded NLC) was obtained by emulsification ultrasonic dispersion method. The selected batch was suitably characterized for particle size, polydispersity index, zeta potential, Entrapment efficiency, Drug release study, and permeability study. The crystallization of the drug in the furosemide cyclodextrin complex (FU–CD complex) and the co-evaporation Furosemide- β-cyclodextrin-loaded NLC (FU–β-CD-COE-loaded NLC) was investigated by differential scanning calorimetry (DSC). The in vitro release study was carried out. Results: The FU–β-CD-COE-loaded NLC and FU–HP-β-CD-COE-loaded NLC (Hydroxypropyl) presented a superior physicochemical property and were selected for further study. The in vitro release study of the above selected batches exhibited a higher dissolution rate in the pH 5.8 phosphate buffer than Furosemide suspension and FU–NLC. The permeability studies of abovementioned batches were compared with FU-Suspension. Conclusion: The novel formulation considerably enhanced the solubility and permeability of furosemide for oral delivery, and was successfully developed.

Formulation, characterization and in-vitro evaluation of solid lipid nanoparticles for the delivery of a new anticancer agent, 1H-pyrazolo[3,4-d] pyrimidine derivative


 
 
 
 Purpose: To investigate the physicochemical properties and in vitro cytotoxic effect of a potent epidermal growth factor receptor-tyrosine kinase (EGFRWT-TK) inhibitor, 1H-pyrazolo [3,4-d] pyrimidine (FEP) derivative and formulated as solid lipid nanoparticles (SLNs) using stearic acid (ST) or glycerylmonostearate (GMS).
 Methods: The SLNs were prepared by hot homogenization and sonication method. The effect of formulation variables on particle size, zeta potential and polydispersity index (PDI) of SLNs were studied, and an optimized formulation selected. Drug-excipient interactions were assessed by differential scanning calorimetry (DSC) and Fourier Transform Infrared (FTIR). Mammary gland breast cancer (MCF-7) and human colon cancer (HCT116) human cell lines were used to evaluate the cytotoxic activity of the free and FEP-loaded SLNs.
 Results: The particle size of the SLNs was in the range of 138 - 819 nm, while zeta potential varied from -15 to -20 nm. FEP-loaded SLNs exhibited significant cytotoxic effect compared to the free drug and doxorubicin in the two cell lines (p < 0.05). The activity was higher in HCT116 compared with MCF-7 cells (p < 0.007). The concentration of FEP loaded SLNs, free drug and doxorubicin that showed 50 % inhibition (IC50) for breast cancer cells were 1.06 ± 0.09, 2.58 ± 0.16 and 3.75 ± 0.4 μg/ml, respectively.
 Conclusion: The findings show that FEP-loaded SLNs have greater in-vitro cytotoxic activity than the free FEP, and thus, might improve cancer therapy in humans.
 
 
 

A comparative in vivo Evaluation of Anti-Alzheimer Activity of Bacopa Extract and its Solid Lipid Nanoparticles

Background: Bacopa monnieri (Brahmi; family Scrophulariaceae) is a well-known plant known for its nootropic activity. Delivery of Bacosides (an active constituent) is limited at the site of action owing to the existence of the Blood-Brain Barrier (BBB). In order to take the Bacoside- Rich Extract (BRE) across BBB, formulated solid lipid nanoparticles (SLNs) were used. Objective: The objective of this work was to evaluate the pharmacokinetic and pharmacodynamic behavior (in vivo potential) of the prepared SLNs containing BRE in comparison to BRE alone for the treatment of Alzheimer’s disease. Methods: Swiss albino male mice (25-30 gm) were used for the study. The pharmacokinetic, as well as pharmacodynamic evaluation of formulated SLNs, were performed in comparison to BRE in a scopolamine-induced amnesia model. Results: BRE-loaded SLNs were found to be significantly more effective than BRE in alleviating neurodegeneration. The pharmacokinetic study revealed the improved bioavailability of prepared SLNs with the potential of sustaining the drug release in mice for an extended period of time. Conclusion: The results demonstrated that the SLNs can be considered as a potential delivery system for taking BRE across the BBB to treat Alzheimer’s disease.

Formulation and Evaluation of Solid Lipid Nanoparticles for controlled delivery of Zidovudine

Zidovudine is one of the chief nucleoside analogue and reverse inhibitor licensed for HIV infection which is placed along with a group of retroviruses. The present research study on Zidovudine solid dosage form surveyed the feasibility utilizing solid lipid nanoparticles (SLNs) for controlled drug delivery of zidovudine embracing glyceryl behenate as lipidic material, tween 80 as a stabilizer and blend of sodium chelate with poloxamer as surfactant. The SLNs were prepared utilizing high pressure homogenization followed by ultrasonication method. The prepared SLNs were characterized by particle size analysis, polydispersity index, zeta potential, DSC, TEM, IR spectroscopy, and X-ray diffractometry. Narrow size distribution of the particles was marked having polydispersity index values under 0.8. The high zeta potential of the different SLN formulations additionally showed their physical stability. Differential scanning calorimetry and powder X-ray diffraction showed decline in crystallinity of drug in the nanoparticle formulation. In vitro release study showed sustained release for up to 12 hours in the SLN formulations prepared. The current study results revealed that zidovudine SLN formulation prepared by high pressure homogenization followed by ultrasonication is a suitable method for controlled drug delivery system.

Novel Curcumin-Resveratrol Solid Nanoparticles Synergistically Inhibit Proliferation of Melanoma Cells.

Polyphenols such as curcumin (Cur) and resveratrol (Res) have been recently shown to have potential to inhibit proliferation of highly aggressive melanoma cells. This study was designed to investigate the feasibility of a topical delivery system, using a solid lipid nanoparticles (SLNs) loaded delivery systems, that can enhance the skin penetration and anti-cancer efficacy of combination of these polyphenols. Negatively charged Cur-Res SLNs with a mean diameter of 180.2 ± 7.7nm were prepared using high shear homogenization method. Cur-Res SLNs were found to be stable up to 2weeks under 4°C. The in vitro release study showed that Res was released five time more than curcumin. The permeability of resveratrol was about 1.67 times that of curcumin from the SLN-gel formulation which was significantly (p < 0.05) lower than from SLN suspension. More than 70% of Cur-Res SLNs were bound to skin locally in a skin binding study suggesting potentially utility of Cur-Res SLNs in the treatment of localized melanoma. In fact, the electrical cell-substrate impedance sensing (ECIS) measurements suggested that Cur-Res combination has potential to stop cell migration of B16F10 melanoma cells. Furthermore, both, Cur-Res SLNs and Cur-Res solution at the ratio of 3:1 demonstrated a strong synergistic inhibition of SK-MEL-28 melanoma cell proliferation. Further evaluation of Cur-Res SLNs in vivo melanoma models are warranted to establish the clinical utility of Cur-Res formulations in melanoma therapy.

Formulation and Evaluation of Solid Lipid Nanoparticles of Olanzapine for the Treatment of Psychosis

Solid lipid nanoparticles (SLN) are typically spherical with an average diameter between 1 nm to 1000 nm in range. It is alternative carrier systems to tradition colloidal carriers, such as liposomes emulsions and polymeric micro and nanoparticles. Olanzapine (OZP) is an atypical antipsychotic agent which is used for treatment of Schizophrenia. Its oral bioavailability is around of 40%. OZP is a class II drug so it having low aqueous solubility. To overcome that problem and to increase its bioavailability, the solid lipid nanoparticles of olanzapine are prepared. Formulation batches designed by modifying type of surfactant ( Span 80, Tween 80), concentration of surfactant, Concentration of co-surfactant, type of lipid ( glyceryl monostearate, Stearic acid), Lipid concentration, speed of stirring and time of stirring using customised design of DOE. The SLN were prepared by high speed homogenization technique, and then characterized by particle size analysis, Drug entrapment efficiency and Drug diffusion study. A formulation containing GMS as a lipid stabilised with tween 80 as surfactant show good drug release, smaller particle size, as compared with other formulations with different lipid and surfactant. The present research findings indicate that OZP loaded solid lipid Nano particulate system for delivery of OZP with better efficacy with minimum adverse effects. Keywords: Olanzapine, SLN, GMS, high speed homogenization and DOE.

Formulation and Evaluation of Solid Lipid Nanoparticles of Bifonazole

The objective of this study was to develop suitable solid lipid nanoparticles for topical delivery of Bifonazole. Bifonazole is an imidazole antifungal drug used in form of ointments. It was patented in 1974 and approved for medical use in 1983. Bifonazole having broad spectrum activity against dermatophytes, moulds, yeasts, fungi and some gram positive bacteria. BFZ SLNs systems were developed by melt emulsification followed by solvent evaporation technique using Compritol 888ATO (Glyceryl behenate) as a solid lipid and Tween 80 as a surfactant. Developed SLNs were evaluated for particle size, polydispersity index (PI), entrapment efficiency (EE) and drug release profiles. Process and formulation parameters were optimized. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) studies were carried out on SLNs to mark the changes in the drug and lipid modifications. The BFZ SLNs based gels were prepared using Carbopol 940 as a gelling agent. The SLNs based gels were evaluated for rheological parameters, in vitro drug release and permeation studies. In vitro antifungal study suggested that the SLNs based gel was more effective in inhibiting growth of Candida albicans. Thus the study concludes that SLNs based gel of BFZ gives a sustained release profile of BFZ and has the potential for treatment of topical fungal infections.

Preparation, statistical optimization, in vitro characterization, and in vivo pharmacological evaluation of solid lipid nanoparticles encapsulating propolis flavonoids: a novel treatment for skin edema

Propolis is a natural resinous product and exerts anti-inflammatory properties. The aim of this study is formulation and characterization of solid lipid nanoparticles (SLNs) encapsulating propolis flavonoids (PFs), intended for topical treatment of skin edema. The nanoparticles were prepared and statistically optimized using Box–Behnken response surface methodology. The in vitro release profile of the optimized nanoparticles was investigated. Cytotoxicity of nanoparticles on HSF-PI 18 cell line was determined. Permeation and penetration of nanoparticles across the incised skin were measured. Finally, the nanoparticles were incorporated into a pharmaceutical hydrogel formulation and the in vivo efficacy in reduction of skin edema was determined. The size, PdI, zeta potential, entrapment efficiency (EE%) and loading efficiency (LE %) of the optimized nanoparticles were 111.3 ± 19.35 nm, 0.34 ± 0.005, −24.17 ± 3.3 mV, 73.5 ± 0.86%, and 3.2 ± 0.27%, respectively. Data obtained through in vitro release study suggested a burst release followed by a prolonged release behavior up to 24 h post incubation time interval. The prepared SLNs exhibited no cytotoxicity on HSF-PI 18 cell line. Ex vivo permeation and penetration study of nanoparticles across the incised skin showed approximately a 2.5-fold and a 3-fold increase in cumulative amount of transport and cumulative amount of skin penetration, respectively. Finally, in vivo studies in rat models, showed a threefold reduction in volume of the edema in animals treated with SLNs. The obtained data revealed that the prepared SNs entrapping PFs, exert high skin targeting effects, prolonged anti-inflammatory properties and therefore high efficiency in treatment of skin edema.

Evaluation of Solid Lipid Nanoparticles Loaded with Praziquantel for Treatment of Schistosoma mansoni Infected Rats

Evaluation of Solid Lipid Nanoparticles Loaded with Praziquantel for Treatment of Schistosoma mansoni Infected Rats

Preparation, characterization and evaluation of solid lipid nanoparticles and niosomes for ING4 gene delivery to MCF-7 cells

Preparation, characterization and evaluation of solid lipid nanoparticles and niosomes for ING4 gene delivery to MCF-7 cells